BioTime Board of Directors Forms Science and Tech Committee

BioTime

today announced that its Board of Directors has recently formed a Science and Technology Committee to oversee the development and commercialization of BioTime's technology and products in regenerative medicine and oncology. The three-member committee will work with officers and employees of BioTime and its subsidiaries to oversee the execution of research and development programs and to review new product and technology development opportunities that become available, to assure the company strategically commits its resources. The committee will regularly report to the Board of Directors and make recommendations to the Board as to the priorities, direction, quality, and execution for BioTime's technology and product development programs, as well as allocations of financial resources and potential acquisitions of new technology and products. The committee is chaired by director Andrew C. von Eschenbach, M.D., the former Commissioner of the U.S. Food and Drug Administration and former Director of the National Cancer Institute. The two other members are director Pedro Lichtinger, CEO of Optimer Pharmaceuticals, and director Neal Bradsher, President of Broadwood Capital, Inc.